Janssen aubmits application to EMA to expand use of DARZALEX(R) (daratumumab)
Janssen-Cilag announced submission of a Type II variation application to the EMA, seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX®▼ (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. August 23, 2016